News &amp; Updates

$Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC$

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

The fixed-dose combination of trifluridine/tipiracil may be feasible for use in the treatment of patients with refractory esophageal squamous cell carcinoma (ESCC), with the drug showing modest clinical activity in the phase II ECTAS study.

Trifluridine/tipiracil polypill shows modest clinical activity against refractory ESCC

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

New drug applications approved by US FDA as of 01 - 15 June 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Drug combinations including venetoclax seem to have a positive impact on health-related quality of life (HRQoL), or at least does not worsen it, in patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, a recent study has found.

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Beta-blocker use reduces daily physical activity

Treatment with beta-blockers in hypertension may decrease daily physical activity but not maximal exercise performance, a study has found.

Beta-blocker use reduces daily physical activity

14 Jun 2022

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

For patients who have undergone continuous‐flow left ventricular assist device (CF‐LVAD) implantation, treatment with amiodarone may do more harm than good, with a recent study showing that it contributes to increased risk of mortality.

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

Adjuvant therapy with 5-fluorouracil (5-FU) and low molecular weight heparin in high-risk patients with rhegmatogenous retinal detachment (RRD) does not help prevent the development of proliferative vitreoretinopathy, as shown in a study.

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

Infection + vaccination = The best protection against COVID-19?

13 Jun 2022 by

Individuals with a prior COVID-19 infection and who are fully vaccinated against COVID-19 appear to have the greatest immunity to the virus, according to the SIREN* study.

Infection + vaccination = The best protection against COVID-19?

13 Jun 2022

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

In patients with gout and end-stage renal disease (ESRD), haemodialysis appears to have an additional benefit of lowering uric acid (UA) levels, a study has found.

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

Pranlukast cuts need for respiratory support in infants with RSV

The use of pranlukast in infants with respiratory syncytial virus (RSV) infections appears to help avoid the need for respiratory support, a recent Japan study has found.

Pranlukast cuts need for respiratory support in infants with RSV